FDA Halts Clinical Trials of REGENXBIO's RGX-121 Gene Therapy for Hunter Syndrome Due to Spinal Abnormalities
Background of FDA's Clinical Hold and Adverse Findings
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on REGENXBIO's gene therapy candidate, RGX-121 [clemidsogene lanparvovec], for Hunter syndrome (MPS II). This safety issue was identified during enhanced MRI monitoring, which was implemented due to previous concerns about neurological tumors in other REGENXBIO trials. Five asymptomatic cystic masses were found in the spines of patients who had participated in the Campsiite clinical trial. While medical experts believe these masses are likely benign and non-invasive, the unexpected anatomical changes observed in long-term treatment groups necessitate further investigation.
Derailment of Accelerated Approval Plans and Regulatory Uncertainty
The clinical hold decision has completely halted REGENXBIO's planned resubmission of RGX-121 for marketing authorization in the third quarter of this year. This therapy had previously received a Complete Response Letter (CRL) from the FDA in February, which denied approval. In June, the FDA agreed to re-evaluate an accelerated approval application based on existing data, raising market expectations. However, the clinical hold has once again shrouded the commercialization timeline in uncertainty. Delays in regulatory discussions and data clarification may significantly postpone the commercial launch compared to initial projections.
Safety Concerns for AAV Vector-Based Gene Therapies
RGX-121 delivers the iduronate-2-sulfatase (IDS) gene via an adeno-associated virus (AAV) 9 vector directly to the central nervous system (CNS). The company has stated that the spinal nodule phenomenon is unlikely to affect its other pipeline products, which differ in administration route and capsid structure. Nevertheless, the market remains deeply skeptical about the long-term side effects and immune responses associated with AAV platform-based gene therapies. This incident highlights how even minor adverse signals can become critical disqualifying factors in the approval of rare disease therapies targeting pediatric patients.
Impact on Partnership Financials and Market Competition
This regulatory setback not only affects REGENXBIO but also raises concerns about the financial structure of its partnership with Nippon Shinyaku and its U.S. subsidiary NS Pharma. The two companies had signed an $810 million licensing agreement to capitalize on commercial synergies following accelerated approval, but milestone payments are now uncertain. Meanwhile, the Hunter syndrome market is dominated by Takeda's Elaprase, with Denali Therapeutics' DNL310 and other blood-brain barrier (BBB)-penetrating therapies rapidly gaining ground. As REGENXBIO delays safety validation, the risk of latecomer competitors capturing market share becomes increasingly severe.
The suspension of REGENXBIO's (RGNX) pivotal Phase 1/2/3 Campsiite clinical trial has delayed its entry into the $800 million to $1.4 billion global Hunter syndrome treatment market, making the $70 million milestone payment from partner Nippon Shinyaku uncertain and triggering a 24% stock plunge. In the medium to long term, this incident has intensified industry-wide doubts about whether long-term safety data for AAV9 vector-based gene therapies can pass regulatory scrutiny. From the perspective of researchers and regulators, it may lead to stricter long-term MRI screening criteria for delayed adverse effects such as asymptomatic spinal cysts, potentially increasing clinical costs for pharmaceutical companies developing similar platforms. From a competitor standpoint, companies like Denali Therapeutics, which are developing BBB-penetrating enzyme replacement therapies such as DNL310, are likely to gain a favorable position in market capture.
Source: FierceBiotech (rss)
https://www.fiercebiotech.com/biotech/fda-clinical-hold-derails-regenxbio-gene-therapy-refiling-plan